NEUROZEN
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NEUROZEN - overview
Established
2015
Location
Seoul, -, South Korea
Primary Industry
Healthcare
About
Based in Seoul, South Korea, and founded by CEOs Sunny Lee and Kunho Lee in 2015, Neurozen Co. develops AI-powered neuroimaging and genetic solutions for the risk assessment and early detection of Alzheimer’s disease. Risk assessment and early detection are crucial to helping target the disease before irreversible brain damage or mental decline has occurred. Neurozen Co.
has an exclusive license to the largest Asian dementia cohort organized by the National Research Center for Dementia (NRCD). The company works with neuroscientists, radiologists, bioinformatics specialists, and dementia experts to develop unique and effective solutions for Alzheimer's disease. In 2021, Neurozen Co. raised KRW 3.
1 billion in series A investment. The company provides detailed genetic analysis for accurate Alzheimer's disease risk assessment through AI-powered neuroimaging and genetic solutions called NeuroXRP Genetic Testing Service and NeuroXgen Alzheimer’s Risk Assessment Service.
Current Investors
DT&Investment, Friend Investment Partners, iPlus Center
Primary Industry
Healthcare
Sub Industries
Alternative Medicine, Diagnostic, Medical & Imaging Laboratories, Healthcare IT, Mental Health Services
Website
www.neurozen.ai
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
NEUROZEN - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.